Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy

  • By

  • Conghui Shang

  • Hao Wang

  • Jindong Chen

  • Shuhui Cao

  • Yingjia Sun

  • Ziyi Sheng

  • Tianqing Chu

  • Liang Zhao

  • December 27, 2025

Share

  • 1

    The study investigates the effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on lung cancer patients with hypertension receiving immune checkpoint inhibitors (ICIs).

  • 2

    The primary endpoint is all-cause mortality, while the secondary endpoint evaluates cardiovascular outcomes related to ICIs-induced cardiotoxicity.

  • 3

    A total of 883 patients undergoing ICI treatment with hypertension were analyzed, with 39 receiving ARNIs and 114 in the control group.

  • 4

    The overall population had a mean age of 67.94 years, predominantly male, with most diagnosed with non-small cell lung cancer (NSCLC) at advanced stages.

  • 5

    The study aims to determine if ARNIs provide survival benefits and reduce cardiotoxicity in lung cancer patients treated with ICIs.

Original Source(s)

Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy

  • by Conghui Shang, Hao Wang, Jindong Chen, Shuhui Cao, Yingjia Sun, Ziyi Sheng, Tianqing Chu, Liang Zhao

  • December 27, 2025

Related Content

FDA guidance spurs adoption of change control plans for radiology AI devices

Investigators examined adoption and public documentation of change control plans for FDA-cleared radiology AI devices.

FDA adds generic valganciclovir oral solution

 The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.

An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial